A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)

Publication | Open Access

DOI Full Paper Access

Citations

References

2019

Year

Jeff P. Sharman, Anna Marina Liberati, Kenichi Ishizawa, Tahira Khan, Jeffery Robbins, Ann Alcasid, Julie A. Rosenberg, Igor Aurer

BioDrugs